Tilray Medical has announced that its wholly-owned subsidiary, FL Group S.R.L., has entered into a partnership with L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A., an Italian pharmaceutical firm specializing in pain therapies and substance dependence.
The partnership is designed to broaden the availability of Tilray Medical cannabis extracts for patients across Italy. Molteni will collaborate with FL Group by providing targeted education on medical cannabis therapies through Molteni's comprehensive network of pharmaceutical, scientific, and medical professionals throughout Italy.
© Tilray Brands
"This partnership reflects our commitment to advancing patient care through strategic collaboration," said Rajnish Ohri, Managing Director, International at Tilray Brands. "By combining FL Group's regulatory and distribution capabilities with Molteni's scientific leadership, we are not only expanding access to high-quality, EU-GMP certified cannabis therapies for patients across Italy but also prioritizing medical cannabis education for pain therapies. Through Molteni's extensive network of healthcare professionals, we aim to empower practitioners with the knowledge and resources needed to support patients seeking effective pain management solutions."
For more information:
Tilray
www.tilray.com
